16 February 2017

March 2017 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **March 2017** Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

New listings

- Lidocaine [lignocaine] hydrochloride (Lidocaine-Claris) inj 1%, 20 ml vial (p'code 2513463) and 2%, 20 ml vial (p'code 2513471) – up to 5 inj available on a PSO
- Ondansetron (Apo-Ondansetron) tab 4 mg (p'code 2511827) and 8 mg (p'code 2511835)
- Potassium chloride (Slow-K) tab long-acting 600 mg (8 mmol) S29, wastage claimable (p'code 2518287)

Changes to restrictions, chemical names and presentations

- Dosulepin [dothiepin] hydrochloride (Dopress) tab 75 mg and cap 25 mg amended chemical name
- Leuprorelin (Lucrin Depot 1 month) inj 3.75 mg prefilled dual chamber syringe, (Eligard 1 Month) 7.5 mg syringe with diluent, (Lucrin Depot 3-month) 11.25 mg prefilled dual chamber syringe, (Eligard 3 Month) 22.5 mg syringe with diluent, (Lucrin Depot 6-month) 30 mg prefilled dual chamber syringe, and (Eligard 6 Month) 45 mg syringe with diluent amended restriction

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Mesalazine	Tab 800 mg	Asacol	
Sodium chloride	Inj 0.9%, 5 ml ampoule	Interpharma*	Multichem and Pfizer
Sodium chloride	Inj 0.9%, 10 ml ampoule	Pfizer*	Multichem
Sodium chloride	Inj 0.9%, 20 ml ampoule	Interpharma*	Multichem and Pharmacia
Water	Inj 10 ml ampoule	Pfizer*	Multichem
Water	Inj 5 ml and 20 ml ampoules	Interpharma*	Multichem

Decreased subsidy

* no subsidy changes for these brands for 1 March 2017.

Increased price and no subsidy increase

Chemical	Presentation	Partially subsidised brands
Alprazolam	Tab 250 mcg, 500 mcg & 1 mg	Xanax

Stock Issue – One Alpha cap 1 mcg and Daivonex oint 50 mcg per g

Leo Pharma has advised PHARMAC that there has been a delay in the delivery of its One Alpha capsules 1 mcg and Daivonex ointment 50 mcg per g, 100 g OP. The stock is expected next week, but this has not been confirmed.

Do you prefer email communications?

If you have not already contacted us and would like to receive future updates by email, please provide your email address to us at enquiry@pharmac.govt.nz. Please put "email or fax preference" in the subject line.

If email is not an option for you, and you would like to continue to receive faxed communications from us, please let us know that too.